Actuate Therapeutics, Inc. (ACTU) stock
Close on Nov 11, 2026Market cap $7.26MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $7.26M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 7.34
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$20.45M
- EPS, diluted
- -$0.88
- Book value per share
- $0.04
- Diluted shares
- 24M
Trading
- Previous close
- $0.30
- Open
- $0.30
- Day's range
- $0.30 – $0.33
- Volume
- 94,914
- Average volume (20 days)
- 504,744
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 1.21
- 52-week range
- $0.29 – $7.90
- RSI (14 days)
- 31.7
- Volatility (1 year)
- 118.7%
- Relative volume
- 0.23×
- WACC
- 10.9%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ACTU | S&P 500 | Difference | ACTU per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -50.5% | -2.4% | −48.1 pts | ||
| 3 months | -70.1% | -1.2% | −68.9 pts | ||
| Year to date | -95.1% | +12.3% | −107.4 pts | ||
| 1 year | -95.1% | +12.4% | −107.6 pts | ||
| 3 years | -94.1% | +78.8% | −172.9 pts | -61.0% | +21.4% |
| 5 years | -94.1% | +75.2% | −169.2 pts | -43.2% | +11.9% |
| 10 years | -94.1% | +311.1% | −405.2 pts | -24.6% | +15.2% |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Actuate Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- News
- Update
- News
About Actuate Therapeutics
Pharmaceutical Preparations
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 beta (GSK-3β). The company centers its research and development on its lead small-molecule product candidate, elraglusib, which functions by blocking signaling pathways essential for cancer cell survival and tumor growth while also regulating anti-tumor immunity. Actuate develops elraglusib across two primary delivery formulations, including an intravenous injection and an oral tablet. Its investigational treatments aim to address adult and pediatric patient populations facing complex oncological conditions such as metastatic pancreatic ductal adenocarcinoma, pediatric refractory solid tumors including Ewing sarcoma and neuroblastoma, metastatic melanoma, and colorectal cancer.
Company profile, executives and historyActuate Therapeutics stock: common questions
What is Actuate Therapeutics's stock price?
ACTU closed at $0.30 on Nov 11, 2026, up 1.75% on the day. Over the past 52 weeks it traded between $0.29 and $7.90.
What is Actuate Therapeutics's market cap?
Actuate Therapeutics was worth $7.26M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ACTU's P/E ratio?
Actuate Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.88), so it has no meaningful P/E ratio.
Does Actuate Therapeutics pay a dividend?
No. Actuate Therapeutics has not paid a cash dividend over the last twelve months.
How has ACTU stock performed over the past year?
Including dividends, ACTU returned -95.1% over the past year, against +12.4% for the S&P 500.
How many ACTU shares are sold short?
1M shares were sold short at the latest FINRA report, 16.24% of the float, or 2.1 days of average trading volume.
Who are Actuate Therapeutics's competitors?
Companies most similar to Actuate Therapeutics by business, industry and size include CLRB, PRLD, ATNM, GALT, IMRX.
See a number that looks wrong?